← Back to Search


Miebo for Dry Eye Syndrome

Phase 4
Research Sponsored by Bausch & Lomb Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up assessed at postop day 30 ± 7 days
Awards & highlights


This trial will look at how Miebo™ affects eye measurements before and after surgery.

Who is the study for?
This trial is for individuals with Dry Eye Syndrome who are preparing for eye surgery. The study aims to include those who need accurate measurements of their eyes (biometry/keratometry) before surgery and want to improve the precision of their vision after the operation.Check my eligibility
What is being tested?
The study is testing Miebo™, a treatment designed to help with Dry Eye Syndrome. It's an open-label Phase 4 trial, meaning everyone knows they're getting Miebo™, and it's being conducted across multiple centers.See study design
What are the potential side effects?
Since specific side effects aren't listed here, generally speaking, treatments for dry eye syndrome can sometimes cause mild burning or irritation in the eyes upon application.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed at postop day 30 ± 7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed at postop day 30 ± 7 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean difference between absolute deviations from predicted refractive error in the study eye.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Miebo treatmentExperimental Treatment1 Intervention
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4

Find a Location

Who is running the clinical trial?

Bausch & Lomb IncorporatedLead Sponsor
252 Previous Clinical Trials
57,237 Total Patients Enrolled
~25 spots leftby Sep 2024